BNP Paribas Financial Markets’s NRC Health Common Stock NRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$44.1K Sell
2,599
-26
-1% -$442 ﹤0.01% 4763
2025
Q4
$49.3K Buy
2,625
+129
+5% +$1.95K ﹤0.01% 4690
2025
Q3
$31.9K Buy
2,496
+1,150
+85% +$17.2K ﹤0.01% 4781
2025
Q2
$22.6K Buy
1,346
+423
+46% +$5.71K ﹤0.01% 4543
2025
Q1
$11.8K Sell
923
-1,155
-56% -$18.5K ﹤0.01% 4675
2024
Q4
$36.7K Sell
2,078
-2,694
-56% -$51.1K ﹤0.01% 4546
2024
Q3
$109K Sell
4,772
-24,275
-84% -$548K ﹤0.01% 3433
2024
Q2
$667K Buy
29,047
+21,554
+288% +$664K ﹤0.01% 2504
2024
Q1
$297K Sell
7,493
-3,986
-35% -$158K ﹤0.01% 3117
2023
Q4
$454K Buy
11,479
+2,095
+22% +$87.7K ﹤0.01% 2843
2023
Q3
$416K Buy
9,384
+5,658
+152% +$247K ﹤0.01% 2818
2023
Q2
$162K Sell
3,726
-2,278
-38% -$100K ﹤0.01% 3088
2023
Q1
$261K Buy
6,004
+1,974
+49% +$87.2K ﹤0.01% 3042
2022
Q4
$150K Sell
4,030
-2,314
-36% -$89.5K ﹤0.01% 3103
2022
Q3
$252K Buy
6,344
+2,848
+81% +$105K ﹤0.01% 3384
2022
Q2
$134K Buy
3,496
+971
+38% +$35.1K ﹤0.01% 3254
2022
Q1
$100K Sell
2,525
-2,552
-50% -$99.9K ﹤0.01% 3359
2021
Q4
$211K Buy
5,077
+2,582
+103% +$112K ﹤0.01% 3380
2021
Q3
$105K Buy
2,495
+2,005
+409% +$101K ﹤0.01% 3254
2021
Q2
$22.5K Sell
490
-1,262
-72% -$60K ﹤0.01% 3503
2021
Q1
$82K Sell
1,752
-782
-31% -$38K ﹤0.01% 3437
2020
Q4
$108K Sell
2,534
-600
-19% -$30.8K ﹤0.01% 3171
2020
Q3
$154K Buy
3,134
+2,632
+524% +$146K ﹤0.01% 2887
2020
Q2
$29.2K Sell
502
-3,445
-87% -$182K ﹤0.01% 3243
2020
Q1
$180K Buy
3,947
+1,920
+95% +$115K ﹤0.01% 2917
2019
Q4
$134K Sell
2,027
-43
-2% -$2.63K ﹤0.01% 3152
2019
Q3
$120K Buy
2,070
+737
+55% +$45.7K ﹤0.01% 3031
2019
Q2
$76.8K Sell
1,333
-976
-42% -$45.2K ﹤0.01% 3186
2019
Q1
$89.1K Buy
2,309
+2,287
+10,395% +$89.6K ﹤0.01% 3188
2018
Q4
$839 Sell
22
-305
-93% -$11.7K ﹤0.01% 3945
2018
Q3
$12.6K Sell
327
-53
-14% -$2.01K ﹤0.01% 3629
2018
Q2
$14.2K Sell
380
-1,670
-81% -$58.2K ﹤0.01% 3636
2018
Q1
$60K Buy
2,050
+103
+5% +$3.46K ﹤0.01% 3470
2017
Q4
$72.6K Buy
1,947
+1,192
+158% +$42.3K ﹤0.01% 3469
2017
Q3
$28.5K Sell
755
-54
-7% -$1.7K ﹤0.01% 3421
2017
Q2
$21.8K Buy
809
+802
+11,457% +$19.6K ﹤0.01% 3612
2017
Q1
$138 Sell
7
-71
-91% -$1.31K ﹤0.01% 3981
2016
Q4
$1.48K Sell
78
-509
-87% -$8.4K ﹤0.01% 3973
2016
Q3
$9.56K Buy
587
+301
+105% +$4.73K ﹤0.01% 3180
2016
Q2
$3.92K Buy
+286
New +$4.03K ﹤0.01% 3355
2016
Q1
Sell
-1,926
Closed -$30.9K 2943
2015
Q4
$30.9K Sell
1,926
-239
-11% -$3.63K ﹤0.01% 3106
2015
Q3
$25.9K Buy
2,165
+1,349
+165% +$17.9K ﹤0.01% 3230
2015
Q2
$11.6K Buy
816
+595
+269% +$8.43K ﹤0.01% 3302
2015
Q1
$3.18K Buy
+221
New +$3.12K ﹤0.01% 3363
2014
Q4
Sell
-669
Closed -$8.7K 2795
2014
Q3
$8.7K Buy
669
+657
+5,475% +$9.04K ﹤0.01% 3653
2014
Q2
$168 Buy
+12
New +$181 ﹤0.01% 3724
2014
Q1
Sell
-127
Closed -$2.39K 3685
2013
Q4
$2.39K Buy
+127
New +$2.23K ﹤0.01% 3576

Other funds holding NRC

BNP Paribas Financial Markets's NRC Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its NRC Health Common Stock (NRC) stake by 0.99% in Q1 2026, selling an estimated $442 and leaving 2,599 shares worth $44.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4763.

BNP Paribas Financial Markets first reported a position in NRC in Q4 2013 and has held it in 47 quarters since. The position peaked at $667K in Q2 2024. 121 funds tracked by Wall St. Rank hold NRC as of Q1 2026.

  • BNP Paribas Financial Markets held 2,599 shares of NRC Health Common Stock worth $44.1K as of Q1 2026.
  • BNP Paribas Financial Markets sold 26 NRC Health Common Stock shares in Q1 2026, an estimated $442.
  • NRC Health Common Stock made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4763 holding.
  • BNP Paribas Financial Markets first reported a position in NRC Health Common Stock in Q4 2013 and has held it in 47 quarters since.
  • BNP Paribas Financial Markets's NRC Health Common Stock position peaked at $667K in Q2 2024.
  • 121 funds tracked by Wall St. Rank held NRC Health Common Stock as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.